<DOC>
	<DOCNO>NCT00606879</DOCNO>
	<brief_summary>SGX523 drug act block function enzyme call MET . MET activity may important growth survival type cancer . This Phase I trial study safety , side effect , best dose SGX523 give patient advanced cancer , well inhibit MET activity tumor .</brief_summary>
	<brief_title>Safety Study SGX523 , Small Molecule Met Inhibitor , Treat Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Subject ability understand , able , willing comply study procedure follow visit , provide write consent Pathologic evidence solid tumor Failed standard therapy deem Investigator suitable participation trial Laboratory value ( obtain within 10 day prior enrollment ) : ANC : &gt; = 1.5 × 109/L ; Platelets : &gt; = 100 × 109/L ; Hemoglobin : &gt; = 10.0 g/dL ( without transfusion ) ; Bilirubin : within normal range ; AST , ALT , alkaline phosphatase : &lt; = 2.5 x ULN without tumor liver involvement ; Serum creatinine : within normal limit ; Calculated creatinine clearance : &gt; = 60 mL/min/1.73 m2 patient creatinine &gt; Institutional Normal Values ; PT/PTT/INR : within normal limits.. Have IHC evidence phosphoMET expression tumor material 12 month old . This requirement entry MTD dose expansion phase . Have residual toxic effect previous therapy , undergo washout period least 5 halflives time administration previous therapy . Pregnant , lactate , may become pregnant Cardiac disease require medical therapy Have major surgery within 4 week prior Day 1 study Have active , uncontrolled bacterial , viral , fungal infection require ongoing systemic therapy Have know active infection HIV , hepatitis B C Have psychiatric seizure disorder would require therapy interfere study participation Have severe concurrent nonmalignant disease could compromise protocol objective , include malabsorptive condition Patients receive prohibit medication list Appendix E , include drug categorize strong inhibitor CYP3A4 A5 drug know high potential risk liver toxicity Have know allergy SGX523 formulation excipients ( croscarmellose sodium , lactose monohydrate magnesium steareate ) Patients receive anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>MET inhibitor</keyword>
	<keyword>Receptor Tyrosine Kinase Inhibitor ( RTKI )</keyword>
</DOC>